Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gynecological malignancies

D L Schaebler1, R J Schilder, R C Young

  • 1Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

Cancer Chemotherapy and Biological Response Modifiers
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cervical epidermal growth factor-receptor (EGF-R) and serum insulin-like growth factor II (IGF-II) levels are potential markers for cervical cancer.

American journal of reproductive immunology (New York, N.Y. : 1989)·2000
Same author

Automated oxyhemoglobin dissociation curve construction to assess sickle cell anemia therapy.

Journal of the National Medical Association·2000
Same author

Up-regulation of epidermal growth factor-receptors (EGF-R) by nicotine in cervical cancer cell lines: this effect may be mediated by EGF.

American journal of reproductive immunology (New York, N.Y. : 1989)·2000
Same author

Fox Chase Network: Fox Chase Cancer Center's community hospital affiliation program.

The oncologist·2000
Same author

Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer.

Seminars in oncology·2000
Same author

Focal sarcoplasmic reticulum calcium stores and diffuse inositol 1,4,5-trisphosphate and ryanodine receptors in human myometrium.

Cell calcium·2000
Same journal

Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

Cancer chemotherapy and biological response modifiers·2005
Same journal

DNA vaccines for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Chemotherapy, cytokines, and biochemotherapy for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Current status of interferon-alpha in the treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
See all related articles

Ovarian tumors of low malignant potential have favorable survival rates. High-risk patients with advanced ovarian cancer may benefit from innovative adjuvant treatments and DNA ploidy analysis for better prognosis.

Area of Science:

  • Gynecologic Oncology
  • Cancer Research
  • Clinical Trials

Background:

  • Ovarian tumors of low malignant potential demonstrate favorable survival compared to invasive epithelial ovarian tumors.
  • Recurrent disease after surgery is infrequent (8%), but certain factors like mucinous histology in stage IA borderline tumors indicate later recurrence and poorer prognosis.
  • High-risk factors for relapse include age >70, stage II/III tumors, and non-serous histology, with long-term survival <75% in this group.

Purpose of the Study:

  • To identify high-risk patient groups for ovarian tumors of low malignant potential who may benefit from innovative adjuvant treatment strategies.
  • To evaluate DNA ploidy as an independent prognostic factor in early-stage ovarian carcinoma using DNA flow cytometric analysis.
  • To assess the efficacy of novel treatment regimens, including paclitaxel and platinum-based agents, for advanced and residual ovarian cancer.

Related Experiment Videos

Main Methods:

  • Analysis of survival data for patients with low malignant potential ovarian tumors, stratified by stage, histology, and age.
  • DNA flow cytometric analysis to identify prognostic subgroups in early-stage ovarian cancer.
  • Prospective randomized trials evaluating paclitaxel-cisplatin regimens for advanced disease and intraperitoneal chemotherapy for residual disease.
  • Dose-escalation studies of paclitaxel and cisplatin, and evaluation of G-CSF and IL-3 in combination therapies.

Main Results:

  • Patients with stage IA borderline mucinous tumors recurred later with poorer prognosis than serous histology.
  • DNA ploidy emerged as an independent prognostic factor in stage I ovarian carcinoma, aiding in identifying subgroups needing further treatment.
  • Paclitaxel and cisplatin showed higher response rates and longer disease-free survival in advanced ovarian cancer compared to cyclophosphamide and cisplatin.
  • Intraperitoneal chemotherapy demonstrated feasibility for consolidation treatment, while additional cycles of CAP did not significantly improve outcomes for residual disease.

Conclusions:

  • Targeted innovative adjuvant treatment strategies are recommended for high-risk patients with ovarian tumors of low malignant potential.
  • DNA flow cytometry analysis can identify early-stage ovarian cancer subgroups with less favorable prognostic characteristics, guiding treatment decisions.
  • Paclitaxel-based chemotherapy regimens show promise for advanced ovarian cancer, with ongoing research into optimal dosing and scheduling.
  • Further randomized trials are needed to confirm the benefits of intraperitoneal chemotherapy and to establish optimal management for residual ovarian cancer.